Active Biotech AB has presented results related to the cancer project Anyara where the effect of Anyara was studied in combination with other established tumour therapies in experimental models of cancer.

The presentation was made at IBC's 6th Annual Antibody Therapeutics Conference held in San Diego, USA, December 9-11.

The results show that Anyara can be effectively combined with other established tumour therapies like docetaxel (Taxotere), bevacizumab (Avastin) and sunitinib (Sutent). Anyara, combined with any of these products, had superior anti-tumour activity compared to single agent therapy.

Anyara is presently developed primarily for the treatment of Renal Cell Cancer. A pivotal phase-III study, which will encompass a total of 500 patients, is currently ongoing.

Tomas Leanderson, president & CEO of Active Biotech said, "A fusion protein between a 5T4 binding antibody fragment and an engineered superantigen (Anyara) is a targeted immunotherapy effective alone and in combination with other cancer therapies."

Anyara is a TTS (Tumour Targeting Superantigens) compound that makes the treatment of cancer tumour-specific. The development of Anyara is mainly focused on renal cancer.

Active Biotech AB, headquartered in Sweden, is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer.